Ignite Creation Date:
2025-12-24 @ 7:55 PM
Ignite Modification Date:
2025-12-30 @ 12:06 PM
Study NCT ID:
NCT05727904
Status:
RECRUITING
Last Update Posted:
2025-07-08
First Post:
2023-02-06
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
Sponsor:
Iovance Biotherapeutics, Inc.
Organization:
Conditions & Keywords Data
Conditions:
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Tumor Infiltrating Lymphocytes | View |
| None | TIL | View |
| None | Metastatic Melanoma | View |
| None | Unresectable Melanoma | View |
| None | Cell Therapy | View |
| None | Cellular Immuno-therapy | View |
| None | IL-2 | View |
| None | Non-myeloablative lymphodepletion (NMALD) | View |
| None | Check point inhibitor | View |
| None | Melanoma | View |
| None | Lifileucel | View |
| None | Stage III Melanoma | View |
| None | Stage IV Melanoma | View |
| None | Skin cancer | View |
| None | Skin cancer types | View |
| None | Malignant melanoma | View |
| None | Autologous Adoptive Cell Therapy | View |
| None | Autologous Adoptive Cell Transfer | View |
| None | LN-144 | View |
| None | Pembrolizumab | View |
| None | Pembro | View |
| None | Adjuvant/Neo-adjuvant | View |
| None | BRAF/MEK | View |
| None | ICI | View |
| None | BRAF v600 | View |
| None | Immune checkpoint inhibitor | View |
| None | Tumor infiltrating T-cells | View |
| None | TILVANCE | View |
| None | TILVANCE-301 | View |